{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:06:47Z","timestamp":1794330407273,"version":"4.9.0"},"reference-count":97,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Clear cell renal cell carcinoma (ccRCC) demonstrates substantial molecular and clinical heterogeneity, limiting the prognostic accuracy of conventional staging system and complicating treatment selection. CT-based radiomics and radiogenomics have emerged as promising non-invasive approaches for predicting molecular biomarkers. This review aimed to evaluate the current evidence regarding CT-based radiogenomics for the prediction of molecular markers in ccRCC, with emphasis on methodological approaches, predictive performance, and clinical applicability. Materials and Methods: A comprehensive literature search of PubMed\/MEDLINE, Scopus, and Cochrane Library databases was performed for original studies published between January 2012 and December 2025. Eligible studies included patients with histopathologically confirmed ccRCC, performed CT-based radiomics feature extraction, and investigated molecular or genetic biomarkers using machine learning (ML) methods. Data regarding CT acquisition phase, segmentation strategy, radiomics features, ML algorithms, investigated biomarkers, and model performance metrics were extracted. Results and Discussion: Twenty-five retrospective studies were included. CT-based radiomics demonstrated promising performance in predicting gene mutations, including Von Hippel\u2013Lindau (VHL), Polybromo 1 (PBRM1), BRCA1-associated protein 1 (BAP1), SET domain containing 2 (SETD2), and Lysine demethylase 5C (KDM5C), with reported area under the curve (AUC) values reaching 0.987. Radiogenomic models also showed utility in assessing hypoxia-related pathways, lipid metabolism signatures, programmed cell death profiles, immune-related markers, and tumor microenvironment characteristics, including programmed death-ligand 1 (PD-L1), Cluster of Differentiation 68 (CD68+) tumor-associated macrophages (TAMs), Cytotoxic T-Lymphocyte\u2013Associated Protein 4 (CTLA-4), Forkhead Box P3 (FOXP3), and Ki-67 proliferation index. Predictive performance varied across biomarkers, with AUCs generally ranging from 0.68 to 0.91. Random Forest (RF), Logistic Regression (LR), Support Vector Machine (SVM), Adaptive Boosting (AdaBoost), and Gradient Boosting algorithms were most commonly applied. Conclusions: CT-based radiogenomics represents a promising non-invasive tool for molecular characterization and risk stratification in ccRCC. Standardized multicenter prospective studies, methodological homogeneity, and external validation are required before routine clinical implementation.<\/jats:p>","DOI":"10.3390\/medicina62071349","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:28:27Z","timestamp":1783927707000},"page":"1349","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CT-Based Radiomics for Prediction of Molecular Markers in Clear Cell Renal Cell Carcinoma: A Comprehensive Review"],"prefix":"10.3390","volume":"62","author":[{"given":"Ekaterini","family":"Boukali","sequence":"first","affiliation":[{"name":"Department of Clinical Radiology, University Hospital of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-3480","authenticated-orcid":false,"given":"Petros","family":"Koumpis","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, University Hospital of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5726-3246","authenticated-orcid":false,"given":"Eleni","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyrysthenis","family":"Vartholomatos","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, University Hospital of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-4481","authenticated-orcid":false,"given":"George A.","family":"Alexiou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-3706","authenticated-orcid":false,"given":"Maria I.","family":"Argyropoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina C.","family":"Tsili","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","unstructured":"Bex, A., Abu-Ghanem, Y., Bedke, J., Breen, D.J., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., and Lund, L. (2026). EAU Guidelines on Renal Cell Carcinoma, European Association of Urology. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Renal-Cell-Carcinoma-2026.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: Incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_3","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00345-018-2309-4","article-title":"Prognostic factors and prognostic models for renal cell carcinoma: A literature review","volume":"36","author":"Klatte","year":"2018","journal-title":"World J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.6004\/jnccn.2020.0043","article-title":"NCCN Guidelines Insights: Kidney cancer, version 1.2021","volume":"18","author":"Motzer","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.ju.0000165572.38887.da","article-title":"Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system","volume":"174","author":"Lam","year":"2005","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Posada Calder\u00f3n, L., Eismann, L., Reese, S.W., Reznik, E., and Hakimi, A.A. (2023). Advances in imaging-based biomarkers in renal cell carcinoma: A critical analysis of the current literature. Cancers, 15.","DOI":"10.3390\/cancers15020354"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13244-025-02164-6","article-title":"From radiomics to radiogenomics: Decoding renal cell carcinoma biology for precision medicine\u2014A narrative review","volume":"16","author":"He","year":"2025","journal-title":"Insights Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition\u2014Novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: Findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43\u201349.","DOI":"10.1038\/nature12222"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1002\/mco2.722","article-title":"Radiogenomics: Bridging the gap between imaging and genomics for precision oncology","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Guarnera, A., Ius, T., Romano, A., Bagatto, D., Denaro, L., Aiudi, D., Iacoangeli, M., Palmieri, M., Frati, A., and Santoro, A. (2025). Advanced MRI, radiomics and radiogenomics in unravelling incidental glioma grading and genetic status: Where are we?. Medicina, 61.","DOI":"10.3390\/medicina61081453"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Saxena, S., Jena, B., Gupta, N., Das, S., Sarmah, D., Bhattacharya, P., Nath, T., Paul, S., Fouda, M.M., and Karla, M. (2022). Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine. Cancers, 14.","DOI":"10.3390\/cancers14122860"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.acra.2024.11.072","article-title":"Interpretable CT radiomics-based machine learning model for preoperative prediction of Ki-67 expression in clear cell renal cell carcinoma","volume":"32","author":"Xv","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13244-025-01980-0","article-title":"CT-based AI framework leveraging multi-scale features for predicting pathological grade and Ki67 index in clear cell renal cell carcinoma: A multicenter study","volume":"16","author":"Yang","year":"2025","journal-title":"Insights Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wu, Y., Shieh, A., Cen, S., Hwang, D., Lei, X., Pawan, S.J., Aron, M., Gill, I., Wallace, W.D., and Kuo, C.-C.J. (2025). Prediction of PD-L1 and CD68 in Clear Cell Renal Cell Carcinoma with Green Learning. J. Imaging, 11.","DOI":"10.3390\/jimaging11060191"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-025-01214-y","article-title":"Integration of multi-scale radiomics and deep learning for Ki-67 prediction in clear cell renal carcinoma","volume":"10","author":"Li","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00330-023-10016-4","article-title":"An automatic texture feature analysis framework of renal tumor: Surgical, pathological, and molecular evaluation based on multi-phase abdominal CT","volume":"34","author":"Yang","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, B., Zhou, M., Guo, L., Huang, H., Sun, X., Peng, Z., Wu, D., and Chen, W. (2024). An integrated machine learning framework identifies prognostic gene pair biomarkers associated with programmed cell death modalities in clear cell renal cell carcinoma. Front. Biosci. (Landmark Ed.), 29.","DOI":"10.31083\/j.fbl2903121"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.acra.2023.10.008","article-title":"Radiomics model for predicting FOXP3 expression level and survival in clear cell renal carcinoma","volume":"31","author":"Wang","year":"2024","journal-title":"Acad. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111433","DOI":"10.1016\/j.ejrad.2024.111433","article-title":"Radiogenomic analysis based on lipid metabolism-related subset for non-invasive prediction for prognosis of renal clear cell carcinoma","volume":"175","author":"He","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40644-024-00744-1","article-title":"Radiomics nomogram based on CT radiomics features and clinical factors for prediction of Ki-67 expression and prognosis in clear cell renal cell carcinoma: A two-center study","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000534078","article-title":"Radiomics correlation to CD68+ tumor-associated macrophages in clear cell renal cell carcinoma","volume":"102","author":"Shieh","year":"2024","journal-title":"Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.acra.2024.01.036","article-title":"Computed tomography-based radiomics to predict FOXM1 expression and overall survival in patients with clear cell renal cell carcinoma","volume":"31","author":"Zhao","year":"2024","journal-title":"Acad. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.1002\/cam4.5449","article-title":"Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma","volume":"12","author":"He","year":"2023","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000530719","article-title":"Radiogenomic associations in clear cell renal cell carcinoma: An exploratory study","volume":"101","author":"Liu","year":"2023","journal-title":"Oncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13244-023-01465-y","article-title":"Automatic analysis framework based on 3D-CT multi-scale features for accurate prediction of Ki67 expression levels in substantial renal cell carcinoma","volume":"14","author":"Yang","year":"2023","journal-title":"Insights Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40644-023-00594-3","article-title":"Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: Insights from the TRACERx Renal study","volume":"23","author":"Orton","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100440","DOI":"10.1016\/j.ejro.2022.100440","article-title":"Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma","volume":"9","author":"Varghese","year":"2022","journal-title":"Eur. J. Radiol. Open"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gao, J., Ye, F., Han, F., Jiang, H., and Zhang, J. (2022). A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.956679"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.18632\/aging.202752","article-title":"Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma","volume":"13","author":"Zeng","year":"2021","journal-title":"Aging"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gao, J., Ye, F., Han, F., Wang, X., Jiang, H., and Zhang, J. (2021). A novel radiogenomics biomarker based on hypoxic-gene subset: Accurate survival and prognostic prediction of renal clear cell carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.739815"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Feng, Z., Zhang, L., Qi, Z., Shen, Q., Hu, Z., and Chen, F. (2020). Identifying BAP1 mutations in clear-cell renal cell carcinoma by CT radiomics: Preliminary findings. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00279"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0284185119881742","article-title":"Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas","volume":"61","author":"Kocak","year":"2020","journal-title":"Acta Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e3494","DOI":"10.1002\/jgm.3494","article-title":"Transcriptome mapping of renal clear cell carcinoma revealed by machine learning algorithm based on enhanced computed tomography images","volume":"25","author":"Yang","year":"2023","journal-title":"J. Gene Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"W55","DOI":"10.2214\/AJR.18.20443","article-title":"Radiogenomics in clear cell renal cell carcinoma: Machine learning\u2013based high-dimensional quantitative CT texture analysis in predicting PBRM1 mutation status","volume":"212","author":"Kocak","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215008","DOI":"10.1088\/1361-6560\/aae5cd","article-title":"Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model","volume":"63","author":"Chen","year":"2018","journal-title":"Phys. Med. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"041009","DOI":"10.1117\/1.JMI.2.4.041009","article-title":"Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features","volume":"2","author":"Ghosh","year":"2015","journal-title":"J. Med. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1158\/0008-5472.CAN-11-0757","article-title":"VHL gene mutations and their effects on hypoxia inducible factor HIF\u03b1: Identification of potential driver and passenger mutations","volume":"71","author":"Rechsteiner","year":"2011","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kim, H.S., Kim, J.H., Jang, H.J., Han, B., and Zang, D.Y. (2018). Clinicopathologic significance of VHL gene alteration in clear-cell renal cell carcinoma: An updated meta-analysis and review. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092529"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Carril-Ajuria, L., Santos, M., Rold\u00e1n-Romero, J.M., Rodriguez-Antona, C., and de Velasco, G. (2019). Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12010016"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/KCA-160003","article-title":"Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma","volume":"1","author":"Carlo","year":"2017","journal-title":"Kidney Cancer"},{"key":"ref_48","first-page":"E157","article-title":"Polybromo-1 (PBRM1), a SWI\/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma","volume":"113","author":"Rezende","year":"2014","journal-title":"BJU Int."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Greco, F., D\u2019Andrea, V., Buoso, A., Cea, L., Bernetti, C., Beomonte Zobel, B., and Mallio, C.A. (2024). Advancements in radiogenomics for clear cell renal cell carcinoma: Understanding the impact of BAP1 mutation. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133960"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Liao","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14737159.2015.1068122","article-title":"BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies","volume":"15","author":"Piva","year":"2015","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/gtmb.2017.0176","article-title":"Prognostic and clinicopathological significance of BAP1 protein expression in different types of cancer\u2014A meta-analysis","volume":"22","author":"Wang","year":"2018","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-170008","article-title":"Molecular classification of renal cell carcinoma and its implication in future clinical practice","volume":"1","author":"Casuscelli","year":"2017","journal-title":"Kidney Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1172\/JCI81040","article-title":"Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer","volume":"125","author":"Rondinelli","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00432-025-06240-8","article-title":"Radiogenomic correlation of hypoxia-related biomarkers in clear cell renal cell carcinoma","volume":"151","author":"Shao","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/PAP.0000000000000185","article-title":"Molecular and metabolic basis of clear cell carcinoma of the kidney","volume":"25","author":"Akhtar","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/2159-8290.CD-21-0211","article-title":"Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma","volume":"11","author":"Riscal","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: Mechanisms and potential targets","volume":"20","author":"Tan","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ccell.2021.07.009","article-title":"Tumor heterogeneity","volume":"39","author":"Ogawa","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Su, W., Hong, T., Feng, B., Yang, Z., and Lei, G. (2023). A unique regulated cell death-related classification regarding prognosis and immune landscapes in non-small cell lung cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1075848"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Osanto, S., Qin, Y., Buermans, H.P., Berkers, J., Lerut, E., Goeman, J.J., and van Poppel, H. (2012). Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038298"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4161\/cbt.27314","article-title":"MicroRNA expression signatures of stage, grade, and progression in clear cell RCC","volume":"15","author":"Gowrishankar","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00432-015-1927-0","article-title":"A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma","volume":"141","author":"Ge","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"69551","DOI":"10.18632\/oncotarget.18449","article-title":"Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma","volume":"8","author":"Petrozza","year":"2017","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrurol.2016.193","article-title":"The translational potential of microRNAs as biofluid markers of urological tumours","volume":"13","author":"Fendler","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-016-1868-5","article-title":"Systemic therapy in metastatic renal cell carcinoma","volume":"35","author":"Bedke","year":"2017","journal-title":"World J. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Arneth, B. (2019). Tumor microenvironment. Medicina, 56.","DOI":"10.3390\/medicina56010015"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Shapiro, D.D., Dolan, B., Laklouk, I.A., Rassi, S., Lozar, T., Emamekhoo, H., Wentland, A.L., Lubner, M.G., and Abel, E.J. (2023). Understanding the tumor immune microenvironment in renal cell carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15092500"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Monjaras-Avila, C.U., Lorenzo-Leal, A.C., Luque-Badillo, A.C., D\u2019Costa, N., Chavez-Mu\u00f1oz, C., and Bach, H. (2023). The tumor immune microenvironment in clear cell renal cell carcinoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097946"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lasorsa, F., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S.D., Crocetto, F., Tataru, O.S., Autorino, R., Battaglia, M., and Ditonno, P. (2023). Cellular and molecular players in the tumor microenvironment of renal cell carcinoma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123888"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wen, H., Zheng, S., Zhu, X., Wang, L., and Chen, D. (2025). Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1643533"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Simonaggio, A., Epaillard, N., Pobel, C., Moreira, M., Oudard, S., and Vano, Y.A. (2021). Tumor microenvironment features as predictive biomarkers of response to immune checkpoint inhibitors (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Cancers, 13.","DOI":"10.3390\/cancers13020231"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wilson, C.M., Ospina, O.E., Townsend, M.K., Nguyen, J., Moran Segura, C., Schildkraut, J.M., Tworoger, S.S., Peres, L.C., and Fridley, B.L. (2021). Challenges and opportunities in the statistical analysis of multiplex immunofluorescence data. Cancers, 13.","DOI":"10.3390\/cancers13123031"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s11255-021-02841-7","article-title":"Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer","volume":"53","author":"Fraune","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"499.e9","DOI":"10.1016\/j.urolonc.2018.07.003","article-title":"Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma","volume":"36","author":"Ueda","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e23562","DOI":"10.4161\/onci.23562","article-title":"Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma","volume":"2","author":"Dannenmann","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Chakiryan, N.H., Kimmel, G.J., Kim, Y., Hajiran, A., Aydin, A.M., Zemp, L., Katende, E., Nguyen, J., Lopez-Blanco, N., and Chahoud, J. (2021). Spatial clustering of CD68+ tumor-associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS ONE, 16.","DOI":"10.1101\/2021.01.04.425197"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-0348-0837-8_9","article-title":"The role of inflammation in kidney cancer","volume":"816","author":"Finke","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e1644109","DOI":"10.1080\/2162402X.2019.1644109","article-title":"Immune checkpoint inhibitors in mCRPC\u2014Rationales, challenges and perspectives","volume":"8","author":"Taghizadeh","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12935-020-01603-2","article-title":"CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12672-025-01831-w","article-title":"FOXP3 as a prognostic marker and therapeutic target in immunogenic cell death modulation for clear cell renal cell carcinoma","volume":"16","author":"Chen","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrc2223","article-title":"The emerging roles of forkhead box (Fox) proteins in cancer","volume":"7","author":"Myatt","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"149251","DOI":"10.1016\/j.bbrc.2023.149251","article-title":"Abnormal expression of FOXM1 in carcinogenesis of renal cell carcinoma: From experimental findings to clinical applications","volume":"692","author":"Shan","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1479-5876-10-200","article-title":"Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma","volume":"10","author":"Xue","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12957-021-02268-5","article-title":"Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma","volume":"19","author":"Song","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"44281","DOI":"10.1038\/srep44281","article-title":"Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: A systematic review and meta-analysis","volume":"7","author":"Xie","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/cncr.22840","article-title":"Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other","volume":"110","author":"Tollefson","year":"2007","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/PAI.0000000000000315","article-title":"Intratumoral heterogeneity for Ki-67 index in invasive breast carcinoma: A study on 131 consecutive cases","volume":"25","author":"Boros","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1349\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:37Z","timestamp":1783929457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071349"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071349","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}